Capella | About
15284
page,page-id-15284,page-template,page-template-full_width,page-template-full_width-php,ajax_fade,page_not_loaded,,qode-theme-ver-9.4.1,wpb-js-composer js-comp-ver-4.12,vc_responsive
 

About

Meet the team behind Capella BioScience

Steve_V3

Steve Holmes

Chief Operating Officer

Dr Steve Holmes has over 25 years experience in the pharmaceutical and biotech industries.

Steve has held senior positions in biotech developing therapeutic antibodies and the therapeutic target portfolio at Oxford Glycosciences (listed on the LSE and NASDAQ and sold to UCB-Celltech), Domantis (bought by GSK for £230M) and Kymab.

He was also at SmithKline Beecham and GSK for 11 years initially heading the monoclonal antibody group and leaving in 2001 as Head of High Throughput Biology Europe. Steve led the research team which discovered BosatriaTM, an IL-5 monoclonal antibody for the treatment of severe eosinophilic asthma.

Steve was an Assistant Professor of Urology at Baylor College of Medicine, and has a BSc in physiology and organic chemistry and a PhD in Endocrinology from the University of Sheffield. He has more than 60 research publications including papers in Nature and has over 40 patents.

Square_Dark_Small
parekh-raj_s

Raj Parekh

Clinical and Scientific Advisory Group

Raj joined Advent Life Sciences in 2005, bringing over 20 years of experience as an entrepreneur and investor in the life sciences.

Following an academic career in molecular medicine at Oxford University, Raj co-founded Oxford GlycoSciences which became listed on the LSE and NASDAQ.

Following its sale to UCB-Celltech, he became Chairman of Chroma Therapeutics and of Galapagos NV, and a Director of Celldex Therapeutics before joining Advent.

He has served on the Board of several portfolio Companies including Thiakis, Avila, EUSA and Cellnovo.

drakeman-don_s

Don Drakeman

Clinical and Scientific Advisory Group

During his 25 years in the industry, Don has overseen the progress of over 30 innovative new medical products for cancer, infectious disease and inflammation from research concept into clinical trials. Several of them have now become FDA-approved therapeutic products for cancer and other diseases.

In that time, he co-founded two multi-billion dollar biotech companies: Medarex Inc and Genmab A/S. Under his leadership as CEO, Medarex raised over a billion dollars, formed alliances with many pharmaceutical companies, developed numerous therapeutic products and spun-off Genmab, which completed Europe’s largest biotech IPO to date.

Don joined the Advent life sciences team in 2007. With an exceptional record in building biotechnology companies, he takes on a senior non-executive role with Advent portfolio companies. He also sources and reviews new investment opportunities in the US and Europe.

Kevin

Kevin Johnson

Clinical and Scientific Advisory Group

Kevin has been working with Index Ventures since 2003. He focuses on life sciences, especially drug development companies, and including Acutus Inc., B3NGF, Levicept Ltd and PanGenetics (acquired by Abbott).

Prior to joining Index, Kevin was CEO of PanGenetics, a Netherlands-based antibody development company and Index investment.  He was part of the team at Cambridge Antibody Technology (CAT), becoming head of research in 1994. In 1997 he was appointed to the board as Research Director and Chief Technology Officer. He led development of CAT’s platform technologies and their application in the discovery of a number of human antibodies currently in clinical development

Two of these, Humira (Abbott Pharmaceutical) and Benlysta (HGS, GSK), are now on the market. He was part of the management team that floated CAT on the London Stock Exchange.

Kevin graduated in Molecular Biology from Edinburgh University and has a PhD in Pathology from Cambridge University.

We are Capella BioScience

Innovation through technology

Our strategy is to use innovative technologies to develop novel medicines based on monoclonal antibodies (mAbs) to the next generation of important therapeutic targets in oncology and autoimmune disease.

Our leadership team have proven track records of successfully developing marketed therapeutic biologics and growing multibillion dollar companies.

Founded in 2014, by Advent Life Sciences and Index Ventures, our mission is to advance our pipeline of first-in-class mAb therapeutics in areas of high unmet medical need.

Innovation0%
Experience0%
Technology0%